NNNN HealthcareBeta data

Anbio Biotechnology

$3.59+2.14%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: Germany
Market cap: 157.3M USD
Enterprise value: 139.3M USD
Full-time employees: 27

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Operating margin at a 4-year high. 67% in 2025, the best of the last 4 years.
Anbio Biotechnology kept 67% of revenue as operating profit in 2025, its highest in the 4 years of filings we have.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Wide margins. Operating margin 67% (fiscal year to Dec 2025) vs a peer median of 7.1%.Operating margin 67% (fiscal year to Dec 2025) vs peers 7.1%.
Anbio Biotechnology keeps 67% of revenue as operating profit, more than 95% of peers (median 7.1%).

StockQuotient Score

—Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Growth

Is it growing?

11/100

Weak

2/3 inputs reported · Partial data

Since last year: ▲ Stronger

12-month revenue up 5.6%

Why

Weaker than most peers on:

▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth-28.4%

SEC filings · 3 years to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -3.70Sector median: 0.0584 · MAD: 0.0840

Revenue growth5.6%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -0.05Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

95/100

Strong

3/3 inputs reported · High confidence

Since last year: ▲ Stronger

Operating margin rose 42.3 points to 66.7%

Why

Stronger than most peers on:

▲ Operating margin
▲ ROA
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin66.7%

SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.16Sector median: 0.0706 · MAD: 0.1217

Return on assets21.2%

SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital20.4%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score 1.56Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin87.2%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity27.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Anbio Biotechnology

Is Anbio Biotechnology getting weaker?: Its latest SEC filing (Apr 7, 2026) got stronger: operating margin rose 42.3 points to 66.7%.
How is Anbio Biotechnology valued vs its peers?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
Is Anbio Biotechnology growing?: More slowly than most of its peers. Growth scores 11/100 against 1,393 healthcare peers. 3-year revenue growth -28.4% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -28.4% vs peers 5.8% (weaker than 100% of peers).
How profitable is Anbio Biotechnology?: More profitable than most of its peers. Profitability scores 95/100 against 1,393 healthcare peers. Operating margin 66.7% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 66.7% vs peers 7.1% (stronger than 95% of peers).
How risky is Anbio Biotechnology?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).

Latest filing: what changed

Year ended Dec 31, 2025 · filed Apr 7, 2026 · compared with the year ended Dec 31, 2024

Got stronger

Operating margin rose 42.3 points to 66.7%

	Previous year	Latest year	Change
Revenue (12 months)	8.2M USD	8.6M USD	+5.6%
Net income (12 months)	2.4M USD	6.4M USD	+169.9%
Operating margin	24.4%	66.7%	+42.3 pts
Cash	11.8M USD	7.8M USD	−34.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	53.4%	50.1%	71.9%	87.2%	▲ 15 pts
Operating margin	43.3%	29.2%	24.4%	66.7%	▲ 42 pts
Net margin	42.5%	33.6%	29.0%	74.1%	▲ 45 pts
Return on assets (ROA)	—	14.3%	12.5%	21.2%	▲ 8.6 pts
Return on equity (ROE)	79.8%	15.2%	13.8%	21.2%	▲ 7.4 pts
Current ratio	—	15.86×	10.71×	344.31×	▲ >999%
Interest coverage	1274.61×	—	—	—	—

NNNN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Operating margin at a 4-year high. 67% in 2025, the best of the last 4 years.

Anbio Biotechnology kept 67% of revenue as operating profit in 2025, its highest in the 4 years of filings we have.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Wide margins. Operating margin 67% (fiscal year to Dec 2025) vs a peer median of 7.1%.Operating margin 67% (fiscal year to Dec 2025) vs peers 7.1%.

Anbio Biotechnology keeps 67% of revenue as operating profit, more than 95% of peers (median 7.1%).

Questions investors ask about Anbio Biotechnology

Is Anbio Biotechnology getting weaker?

Its latest SEC filing (Apr 7, 2026) got stronger: operating margin rose 42.3 points to 66.7%.

How is Anbio Biotechnology valued vs its peers?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

Is Anbio Biotechnology growing?

More slowly than most of its peers. Growth scores 11/100 against 1,393 healthcare peers. 3-year revenue growth -28.4% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -28.4% vs peers 5.8% (weaker than 100% of peers).

How profitable is Anbio Biotechnology?

More profitable than most of its peers. Profitability scores 95/100 against 1,393 healthcare peers. Operating margin 66.7% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 66.7% vs peers 7.1% (stronger than 95% of peers).

How risky is Anbio Biotechnology?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

Previous year

Latest year

Change

Revenue (12 months)

8.2M USD

8.6M USD

+5.6%

Net income (12 months)

2.4M USD

6.4M USD

+169.9%

Operating margin

24.4%

66.7%

+42.3 pts

Cash

11.8M USD

7.8M USD

−34.0%

Key ratios

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

53.4%

50.1%

71.9%

87.2%

▲ 15 pts

Operating margin

43.3%

29.2%

24.4%

66.7%

▲ 42 pts

Net margin

42.5%

33.6%

29.0%

74.1%

▲ 45 pts

Return on assets (ROA)

—

14.3%

12.5%

21.2%

▲ 8.6 pts

Return on equity (ROE)

79.8%

15.2%

13.8%

21.2%

▲ 7.4 pts

Current ratio

—

15.86×

10.71×

344.31×

▲ >999%

Interest coverage

1274.61×

—